MGTX
MeiraGTx Holdings plc
NASDAQ · Healthcare · Biotechnology · US
$9.76
+2.52%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$9.81
From 52W high−34.80%
Volume44763.00
Market cap$937.38M
P/E (TTM)12.8x
P/S (TTM)2.4x
Div yield—
Key dataNov 4, 2026
Open
$9.81
From 52W high
−34.80%
Volume
44763.00
Market cap
$937.38M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
3.5x
P/E (TTM)
12.8x
RSI (14)
38.4
MomentumView details →
1D Return
+2.52%
YTD Return
+18.49%
SummaryUpdated Jun 1, 2026
MeiraGTx Holdings plc (NASDAQ:MGTX) is a clinical-stage gene therapy company founded in 2015 and based in New York. The company went public in June 2018 and focuses on developing innovative gene therapies to treat patients with serious diseases, particularly inherited blindness and other ocular conditions, as well as neurodegenerative diseases. MeiraGTx operates at the cutting edge of biotechnology, using advanced genetic engineering techniques to potentially cure diseases that currently have limited or no treatment options.
Similar companies
Latest newsMore news →
MeiraGTx Holdings plc appointed Alan M. Sebulsky as a Class I director effective September 23, 2026, with service on the Science and Technology Committee.42d agoMeiraGTx raised $100 million in equity financing concurrent with the bota-vec acquisition.83d agoMeiraGTx completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for $25 million.83d ago